ArticlePloS one2021
Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- B Cells or T Cells in the Development and Sustenance of Rheumatoid Arthritis: Who is the Potential Contributor?Mediterranean journal of rheumatology · 2026Review
- Targeting NF-κB and JAK/STAT pathways in rheumatoid arthritis: emerging nanocarrier-based drug delivery approaches.Inflammopharmacology · 2026Review
- Exploration of Novel Chemical Spaces to Discover JAK1 Inhibitors: An Ensemble Docking-Guided Deep Learning Approach.ACS omega · 2026Article
- Genetic and Functional Characterization of STAT4 in Rheumatoid Arthritis Patients with Distinct Disease Activity.International journal of molecular sciences · 2025Article
- Effects of Janus Kinase Inhibitors on Rheumatoid Arthritis Pain: Clinical Evidence and Mechanistic Pathways.Biomedicines · 2025Review
- Parvovirus B19 NS1 protein induces synovitis mimicking rheumatoid arthritis.Scientific reports · 2025Article
- Targeting rheumatoid arthritis risk factors with phytochemicals: an anti-inflammatory perspective.Inflammopharmacology · 2025Review
- Deep learning enables automatic detection of joint damage progression in rheumatoid arthritis-model development and external validation.Rheumatology (Oxford, England) · 2025Article
- Using mass cytometry to probe the STAT signaling landscape in circulating immune cells in Rheumatoid Arthritis uncovers signaling dysregulation and correlation with disease activity.Frontiers in medicine · 2025Article
- Monocarboxylate transporter 4 facilitatesiScience · 2024Article
- Comprehensive bioinformatics analysis unveils THEMIS2 as a carcinogenic indicator related to immune infiltration and prognosis of thyroid cancer.Scientific reports · 2024Article
- Th17/1 and ex-Th17 cells are detected in patients with polyarticular juvenile arthritis and increase following treatment.Pediatric rheumatology online journal · 2024Article
- Naringenin ameliorates collagen-induced arthritis through activating AMPK-mediated autophagy in macrophages.Immunity, inflammation and disease · 2023Article
- Long-Circulating Lipid Nanospheres Loaded with Flurbiprofen Axetil for Targeted Rheumatoid Arthritis Treatment.International journal of nanomedicine · 2023Article
- RhoA Promotes Synovial Proliferation and Bone Erosion in Rheumatoid Arthritis through Wnt/PCP Pathway.Mediators of inflammation · 2023Article
- Multilevel Modeling of Joint Damage in Rheumatoid Arthritis.Advanced intelligent systems (Weinheim an der Bergstrasse, Germany) · 2022Article
- A Crowdsourcing Approach to Develop Machine Learning Models to Quantify Radiographic Joint Damage in Rheumatoid Arthritis.JAMA network open · 2022Article
- Network pharmacology-based approach uncovers the JAK/STAT signaling mechanism underlyingAmerican journal of translational research · 2022Article
- Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family.Pharmaceuticals (Basel, Switzerland) · 2021Article
- IL-34 affects fibroblast-like synoviocyte proliferation, apoptosis and function by regulating IL-17.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 11 institutions in 1 country.
Funding
Abstract
Rheumatoid arthritis (RA) is a systemic and incurable autoimmune disease characterized by chronic inflammation in synovial lining of joints. To identify the signaling pathways involved in RA, its disease activity, and treatment response, we adapted a systems immunology approach to simultaneously quantify 42 signaling nodes in 21 immune cell subsets (e.g., IFNα→p-STAT5 in B cells) in peripheral blood mononuclear cells (PBMC) from 194 patients with longstanding RA (including 98 patients before and after treatment), and 41 healthy controls (HC). We found multiple differences between patients with RA compared to HC, predominantly in cytokine-induced Jak/STAT signaling in many immune cell subsets, suggesting pathways that may be associated with susceptibility to RA. We also found that high RA disease activity, compared to low disease activity, was associated with decreased (e.g., IFNα→p-STAT5, IL-10→p-STAT1) or increased (e.g., IL-6→STAT3) response to stimuli in multiple cell subsets. Finally, we compared signaling in patients with established, refractory RA before and six months after initiation of methotrexate (MTX) or TNF inhibitors (TNFi). We noted significant changes from pre-treatment to post-treatment in IFNα→p-STAT5 signaling and IL-10→p-STAT1 signaling in multiple cell subsets; these changes brought the aberrant RA signaling profiles toward those of HC. This large, comprehensive functional signaling pathway study provides novel insights into the pathogenesis of RA and shows the potential of quantification of cytokine-induced signaling as a biomarker of disease activity or treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.